Navigation Links
ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
Date:10/14/2009

ells in a variety of tissues. ZC-701 is a recombinant protein containing ZyStor's proprietary GILT tag fused to GAA, thereby allowing more efficient delivery of GAA to the lysosome of muscle cells. In preclinical research, ZC-701 was found to be both safe and highly efficacious in well-studied animal models. In animal models, preclinical efficacy was seen at doses much lower than those reported for the currently approved drug for the treatment of Pompe disease. It is anticipated that the first-in-human trial of ZC-701 will be conducted in late-onset Pompe patients.

Dr. Barry Byrne, Professor of Pediatrics and Molecular Genetics & Microbiology at the University of Florida College of Medicine, said, "The FDA approval of the ZyStor IND represents an important step in developing an improved treatment for Pompe patients. Clinical studies will show whether this new therapeutic approach provides the same benefit in humans as in preclinical testing."

About ZyStor Therapeutics, Inc.

ZyStor Therapeutics, Inc. is a privately held biotechnology company based in Milwaukee, Wisconsin developing a novel class of targeted protein therapeutics incorporating the Company's proprietary GILT technology that allows more efficient delivery of therapeutic enzymes to the lysosome and is thus applicable to the treatment of lysosomal storage diseases. This proprietary technology is termed Glycosylation Independent Lysosomal Targeting (GILT) because the peptide tag replaces mannose-6-phosphate (M6P) as the moiety normally targeting the lysosome. Use of a peptide targeting strategy not only improves lysosomal delivery of the therapeutic but also offers manufacturing advantages over conventional protein therapeutics for the treatment of LSDs.

This press release contains certain "forward-looking statements" and all forward-looking statements involve risks and uncertainty. Although the Company believes that the assumptions underlying
'/>"/>

SOURCE ZyStor Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
2. Solace Therapeutics, Inc. Announces CE Mark Approval
3. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
4. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
5. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
6. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
7. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
8. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
9. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
10. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
11. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Siemens Healthcare ... solutions to help ... meet deadlines defined within the HITECH provision ... (ARRA). Featuring zero-percent interest terms ... to defer up-front payments associated with their ...
(Date:12/16/2009)... -- Biovista Inc.,today announced that it was awarded ... the 2009 New England Venture Summit, held on ... cutting edge private companies,driving the future of innovation, ... other privately held companies that play a leading ... Clean-tech sectors. , "We ...
(Date:12/16/2009)... Today, Avantium announced the,appointment of Gunnar Staaf ... Gunnar Staaf previously worked at Serentis Ltd, ... in a range of commercial and executive,positions. ... Avantium,s plan to,spin-out its pharmaceutical business. The ... based on its offering of proprietary,crystallization services ...
Breaking Medicine Technology:Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4Biovista Inc. Named Top Innovator in Life Sciences 2Avantium Appoints Gunnar Staaf as CEO Pharma 2Jeremy M Stipkala to Lead Symposium Entitled Patent Law Developments at SERMACS 2009 14458 1Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 1Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 2Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 3Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 4Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 5Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 6Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 7Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 8Escalon 28R 29 Reports Fourth Quarter and Fiscal 2009 Results 5450 9Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 1Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 2Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 3
... BRUSSELS, Belgium, and BRIDGEWATER, N.J., Feb. 19, UCB ... Food and Drug Administration (FDA) approved a New ... solution, a prescription antihistamine indicated for the relief ... well as the,treatment of chronic idiopathic urticaria. XYZAL(R) ...
... Plan for Biomarker Study -, MONTVALE, N.J., ... ) today announced that it plans to,conduct a ... nicotinic alpha-7,partial agonist, on two biomarkers of schizophrenia, ... schizophrenia. The biomarker study,and additional formulation and manufacturing ...
Other Medicine Technology:FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria 2FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria 3FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria 4FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria 5Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 2Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 3Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 4
(Date:12/16/2009)... acids commonly found in fatty fish and algae ... published by the American Psychological Association. The finding ... in people with schizophrenia; bipolar, obsessive-compulsive, and attention-deficit ... the nervous system. , The study, reported ... more evidence that fish is brain food. The ...
(Date:12/16/2009)... time in half, but use in humans is still far ... improve on nature, researchers have built and tested synthetic versions ... trauma or other cases where blood just won,t stop flowing. ... is used in degradable stitches, which dissolve in the body," ... Case Western Reserve University, and lead author of a report ...
(Date:12/16/2009)... Therapy or NSRTSM is found very effective in the alleviation ... asthma, migraines, chronic fatigue and a wide array of skin ... using this holistic therapy including over 50 branded BioVeda Health ... ... MN (Vocus) December 14, 2009 -- BioVeda Health and Wellness ...
(Date:12/16/2009)... percent of children are uninsured, government report finds , , ... six months of this year, 45.4 million Americans of ... -- had no health insurance, according to new National ... 58.4 million (19.4 percent) people of all ages had ... prior to the interview, and 31.9 million (10.6 percent) ...
(Date:12/16/2009)... -- OrthoAccel Technologies, Inc., developers of the ... to enhance orthodontics, announced Alison Davies as its ... Ms. Davies has spent the last fourteen years ... most recently for nine years as a senior ... Invisalign . ,, (Logo: ...
Breaking Medicine News(10 mins):Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4
... ReBuilder,Medical Technologies, Inc. (Pink Sheets: RBRM), an ... device inventor David B.,Phillips, Ph.D., today announced ... facilitation. (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ) ... are outsourcing customer service to,overseas facilities, the ...
... a common,problem, yet the antibiotics physicians prescribe to ... this condition work in only a fraction of,cases. ... a form called,chronic nonbacterial prostatitis, which is particularly ... Harvard Medical School,s Perspectives on Prostate,Disease describes, urologists ...
... Device is the World,s First Accurate Non-Contact Clinical ... Kidz-Med, Inc., a division of,American Scientific Resources, (ASFX-OTC) ... thermometer, the first non-contact clinical,thermometer in the world, ... revolutionary Thermofocus 5-in-1, made in Italy and long,recommended ...
... at the Hebrew University of Jerusalem have developed a ... holds out promise of providing improved movements of natural ... or paralyzed. , Neuroscientists have long been working ... brain activity and behavior, and especially between neural activity ...
... Davis School of Gerontology found that caregivers of different ... as a result of tending to a family member ... in the September 2007 journal Aging & Mental Health, ... and white caregivers. , A population-based sample of ...
... Under 5 in Madagascar to Sleep Under Bed Nets, ... and,Sumitomo Chemical have teamed up to contribute to the ... between October 22-29. Led by the Malagasy government, ... months to five years old receives a bed net. ...
Other Medicine News:Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 2Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 3Health News:Antibiotics May Not Help Men's Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 3Health News:Brain measurements could lead to better devices to move injured or artificial limbs 2Health News:Brain measurements could lead to better devices to move injured or artificial limbs 3Health News:USC study examines effects of caregiving 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 3
Functional trainer...
... Pore Gradient Lipoprotein Electrophoresis System (PGGE) ... such as low density lipoproteins (LDL) ... on particle size using nondenaturing pore ... standard PAGE and short DNA sequencing ...
... System separates HDL into large, intermediate and ... each subfraction. The test procedure is simple ... three hours. A color coded profile is ... seen., ,The Lipoprint HDL Kit contains all ...
... a high resolution diagnostic test for cholesterol components ... The test procedure is simple and can be ... value is clearly flagged. A color coded profile ... LDL in red and the good HDL in ...
Medicine Products: